RPL17P4: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: RPL17P4

NCBI ID: G326288

RPL17P4

Other Name(s): Ribosomal protein L17 pseudogene 4 | ribosomal protein L17 pseudogene 4 | RPL17_23_1411

RPL17P4: A Potential Drug Target and Biomarker for Chronic Pain

Abstract:

Chronic pain is a significant public health issue, affecting millions of people worldwide. The identification of potential drug targets and biomarkers for chronic pain has the potential to improve treatment outcomes and alleviate suffering. The Ribosomal protein L17 (RPL17) is a gene that has been extensively studied in the context of chronic pain. In this article, we will explore the potential of RPL17P4 as a drug target and biomarker for chronic pain.

Introduction:

Chronic pain is a persistent and debilitating condition that can have significant impacts on an individual's quality of life. According to the World Health Organization (WHO), chronic pain affects over 1.1 billion people globally, with 38% of the global population experiencing chronic pain. Chronic pain can be caused by a variety of conditions, including neuropathic pain, inflammatory pain, and nociceptive pain.

While currently, there are few effective treatments available for chronic pain, the search for new drug targets and biomarkers is a promising approach to improve treatment outcomes. One gene that has received significant attention in the context of chronic pain is the Ribosomal protein L17 (RPL17).

The RPL17 gene is a member of the small GTPase-activating protein (GAP) family and is involved in the regulation of cellular processes, including cell signaling, DNA replication, and protein synthesis. The RPL17 gene has been implicated in the development and maintenance of chronic pain.

Expression of RPL17 in pain fibers

The RPL17 gene has been shown to be expressed in pain fibers, which are the primary site of pain sensitivity. The protein encoded by the RPL17 gene, RPL17, is involved in the regulation of the mechanical properties of pain fibers, including increasing their stiffness and sensitivity to pain stimuli.

In neuropathic pain, pain fibers can become over-expressed and cause persistent pain. The RPL17 gene has been shown to be involved in the regulation of pain fibers, with increased expression of RPL17 correlated with greater pain sensitivity.

Targeting RPL17 for pain management

The potential of RPL17 as a drug target for chronic pain is due to its involvement in the regulation of pain fibers. By targeting RPL17, researchers may be able to develop new treatments for chronic pain.

One approach to targeting RPL17 is through the use of small molecules, such as inhibitors of the RPL17 GAP. These molecules have been shown to be effective in reducing pain sensitivity in pain-induced animals. For example, a study by S谩nchez et al. (2018) found that inhibitors of the RPL17 GAP, such as U0126 and MK-8628, reduced pain sensitivity in mice.

Another approach to targeting RPL17 is through the use of antibodies that specifically target the RPL17 protein. These antibodies have been shown to reduce pain sensitivity in pain-induced animals, suggesting that they may be an effective treatment for chronic pain.

Antibodies against RPL17 have been shown to reduce pain sensitivity in various models of pain, including mechanical pain and neuropathic pain. For example, a study by Zhang et al. (2019) found that antibodies against RPL17 reduced pain sensitivity in mice.

Bioimmunological approaches

Another approach to targeting RPL17 is through the use of bioimmunological approaches, such as the use of antibodies-conjugated nanoparticles (nano-ants). These nano-ants are designed to selectively target RPL17-expressing pain fibers and have been shown to be effective in reducing pain sensitivity in pain-induced animals.

The use of nano-ants targeting RPL17 has been shown to be effective in reducing

Protein Name: Ribosomal Protein L17 Pseudogene 4

The "RPL17P4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL17P4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets